牛牛AI助理已提取核心訊息
On February 7, 2024, Panbela Therapeutics, Inc. reported to the SEC that its Compensation Committee approved retention bonuses for employees, including CEO Jennifer K. Simpson and CFO Susan Horvath. The bonuses are contingent on employment through August 15, 2024, or until a change in control of the company occurs. Simpson and Horvath are set to receive $54,281 and $34,299 respectively. Additionally, the Committee certified the cash incentive compensation for fiscal year 2023, with Horvath receiving $119,394. Despite being eligible for $227,084, Simpson waived her cash incentive for 2023. The retention agreement details were filed with the SEC and are incorporated into the report.
On February 7, 2024, Panbela Therapeutics, Inc. reported to the SEC that its Compensation Committee approved retention bonuses for employees, including CEO Jennifer K. Simpson and CFO Susan Horvath. The bonuses are contingent on employment through August 15, 2024, or until a change in control of the company occurs. Simpson and Horvath are set to receive $54,281 and $34,299 respectively. Additionally, the Committee certified the cash incentive compensation for fiscal year 2023, with Horvath receiving $119,394. Despite being eligible for $227,084, Simpson waived her cash incentive for 2023. The retention agreement details were filed with the SEC and are incorporated into the report.
2024年2月7日，Panbela Therapeutics, Inc.向美國證券交易委員會報告說，其薪酬委員會批准了向包括首席執行官詹妮弗·辛普森和首席財務官蘇珊·霍瓦斯在內的員工發放留用獎金。獎金取決於2024年8月15日之前的就業情況，或者直到公司控制權發生變化爲止。辛普森和霍瓦斯將分別獲得54,281美元和34,299美元。此外，委員會還認證了2023財年的現金激勵薪酬，霍瓦斯獲得了119,394美元。儘管有資格獲得227,084美元，但辛普森還是放棄了2023年的現金激勵。保留協議的詳細信息已提交給美國證券交易委員會，並已納入報告中。
2024年2月7日，Panbela Therapeutics, Inc.向美國證券交易委員會報告說，其薪酬委員會批准了向包括首席執行官詹妮弗·辛普森和首席財務官蘇珊·霍瓦斯在內的員工發放留用獎金。獎金取決於2024年8月15日之前的就業情況，或者直到公司控制權發生變化爲止。辛普森和霍瓦斯將分別獲得54,281美元和34,299美元。此外，委員會還認證了2023財年的現金激勵薪酬，霍瓦斯獲得了119,394美元。儘管有資格獲得227,084美元，但辛普森還是放棄了2023年的現金激勵。保留協議的詳細信息已提交給美國證券交易委員會，並已納入報告中。
有用
沒用